Pharmaceuticals

Virpax Pharmaceuticals

Virpax Pharmaceuticals Receives NASDAQ Delisting Notice for Not Meeting Shareholder Equity Requirements, Stock Down 87.16% Year-to-Date

Virpax Pharmaceuticals Submits Application to Issue Up to 2.4 Million Shares of Common Stock

Virpax Pharmaceuticals Inc Receives Positive Results from PROBUDUR™ Dosage Range Study

Virpax Pharmaceuticals released FY2024 annual earnings on March 3, 2025 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -70.9102 USD (forecast -82.5 USD)

Virpax Pharmaceuticals released FY2024 Q4 earnings on March 3, 2025 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -9.1781 USD (forecast -6.75 USD)

Virpax Pharmaceuticals Announces Public Offering at $0.20 per Share, Stock Nears 52-Week Low

Virpax Pharmaceuticals released FY2024 Q3 earnings on November 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -10.7695 USD (forecast -13.5 USD)

Virpax Pharmaceuticals released FY2024 9 Months Earnings on November 14 (EST) with actual revenue of 0 USD and EPS of -123.1378 USD

Virpax Pharmaceuticals released FY2024 semi-annual earnings on August 12 (EST), with actual revenue of 0 USD and EPS of -105.9393 USD

Virpax Pharmaceuticals released FY2024 Q2 earnings on August 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -43.6277 USD (forecast -38.25 USD)

Virpax Pharmaceuticals released FY2024 Q1 earnings on May 13 (EST), with actual revenue of 0 USD and EPS of -68.7405 USD

Virpax Pharmaceuticals Inc Announces Probudur™ Maximum Tolerated Dose Study Results

Virpax Pharmaceuticals released FY2023 annual earnings on March 26 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -324.2226 USD (forecast -300 USD)

Virpax Pharmaceuticals released FY2023 Q4 earnings on March 26 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -97.3704 USD (forecast -75 USD)

Virpax Pharmaceuticals released FY2023 Q3 earnings on November 16 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -127.95 USD (forecast -65 USD)

Virpax Pharmaceuticals released FY2023 9 Months Earnings on November 16 (EST), with actual revenue of 0 USD and EPS of -226.8522 USD

Virpax Pharmaceuticals released FY2023 semi-annual earnings on August 14 (EST), with actual revenue of 0 USD and EPS of -98.8986 USD

Virpax Pharmaceuticals released FY2023 Q2 earnings on August 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -66.4425 USD (forecast -40 USD)

Virpax Pharmaceuticals released FY2023 Q1 earnings on May 12 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -32.456 USD (forecast -75 USD)

Virpax Pharmaceuticals released FY2022 Q4 earnings on March 22 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -63.7917 USD (forecast -167.5 USD)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap